Farzana Perwad, MD

Title(s)Professor, Pediatrics
SchoolSchool of Medicine
AddressLocation Required, #4311
Phone415-476-2423
ORCID ORCID Icon0000-0001-7983-0127 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Kasturba Medical College, IndiaMBBS1996Medicine
    Nicklaus Children's Hospital, MiamiMD2001Pediatrics
    University of California San Francisco, San Francisco2005Pediatric Nephrology

    Collapse Overview 
    Collapse Overview
    My research focus is to understand the molecular mechanisms of regulation of phosphorus and vitamin D metabolism in the setting of chronic kidney disease.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Multi-trait Analysis of GWAS for circulating FGF23 Identifies Novel Network Interactions Between HRG-HMGB1 and Cardiac Disease in CKD. medRxiv. 2024 Mar 06. Perwad F, Akwo EA, Vartanian N, Suva LJ, Friedman PA, Robinson-Cohen C. PMID: 38496593; PMCID: PMC10942519.
      View in: PubMed   Mentions:
    2. Burosumab versus conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period. JBMR Plus. 2024 Jan 4; ziad001. Ward WL, Högler HW, Glorieux GF, Portale PA, Whyte WM, Munns MC, Nilsson NO, Simmons SJ, Padidela PR, Namba NN, Cheong CH, Sochett SE, Muroya MK, Tanaka TH, Pitukcheewanont PP, Gottesman GG, Biggin BA, Perwad PF, Chen CA, Merritt MJ, Imel IE. .
      View in: Publisher Site   Mentions:
    3. Multi-Trait Analysis of Mineral Metabolism Markers Identifies Novel Genetic Associations for FGF23. Journal of the American Society of Nephrology. 2023 Nov 1; 34(11S):486-486. Robinson-Cohen RC, Vartanian VN, Akwo AE, Perwad PF. .
      View in: Publisher Site   Mentions:
    4. Multi-Trait Genome-Wide Association Study (GWAS) and Functional Genomics Identifies Novel Genetic Traits and Dynamic Networks for FGF23. Journal of the American Society of Nephrology. 2023 Nov 1; 34(11S):123-124. Perwad PF, Vartanian VN, Akwo AE, Robinson-Cohen RC. .
      View in: Publisher Site   Mentions:
    5. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level. J Clin Endocrinol Metab. 2023 10 18; 108(11):2990-2998. Imel EA, Glorieux FH, Whyte MP, Portale AA, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Chen A, Roberts MS, Ward LM. PMID: 37084401; PMCID: PMC10583998.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Genetic testing in children with nephrolithiasis and nephrocalcinosis. Pediatr Nephrol. 2023 08; 38(8):2615-2622. Gefen AM, Sethna CB, Cil O, Perwad F, Schoettler M, Michael M, Angelo JR, Safdar A, Amlie-Wolf L, Hunley TE, Ellison JS, Feig D, Zaritsky J. PMID: 36688940.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease. J Clin Endocrinol Metab. 2022 08 18; 107(9):e3866-e3876. Laster ML, Rowan B, Chen HC, Schwantes-An TH, Sheng X, Friedman PA, Ikizler TA, Sinshiemer JS, Ix JH, Susztak K, de Boer IH, Kestenbaum B, Hung A, Moe SM, Perwad F, Robinson-Cohen C. PMID: 35587600; PMCID: PMC9387704.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif Tissue Int. 2022 10; 111(4):409-418. Brandi ML, Jan de Beur S, Briot K, Carpenter T, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Imel EA, Ing SW, Insogna K, Ito N, Javaid K, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Portale A, Ralston SH, Tanaka H, Weber TJ, Yoo HW, Sun W, Williams A, Nixon A, Takeuchi Y. PMID: 35927518.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    9. Rickets in a child with prolonged acquired hypothyroidism secondary to Hashimoto's thyroiditis. Endocrinol Diabetes Metab Case Rep. 2022 Aug 01; 2022. Schulmeister C, Lee J, Perwad F, Long R, Srinivasan S. PMID: 35979838; PMCID: PMC9422259.
      View in: PubMed   Mentions:
    10. Association of Genetically Predicted Fibroblast Growth Factor-23 with Heart Failure: A Mendelian Randomization Study. Clin J Am Soc Nephrol. 2022 08; 17(8):1183-1193. Akwo E, Pike MM, Ertuglu LA, Vartanian N, Farber-Eger E, Lipworth L, Perwad F, Siew E, Hung A, Bansal N, de Boer I, Kestenbaum B, Cox NJ, Ikizler TA, Wells Q, Robinson-Cohen C. PMID: 35902130; PMCID: PMC9435988.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    11. Longitudinal Changes in FGF-23 in Children with CKD. Journal of the American Society of Nephrology. 2021 Oct 1; 32(10S):212-212. Perwad PF, Matheson MM, Salusky SI, Jüppner JH, Wolf WM, Warady WB, Furth FS, Ng ND, Portale PA. .
      View in: Publisher Site   Mentions:
    12. Genetic Testing in Children with Nephrolithiasis and Nephrocalcinosis. Journal of the American Society of Nephrology. 2021 Oct 1; 32(10S):613-614. Gefen GA, Sethna SC, Cil CO, Perwad PF, Schoettler SM, Amlie-Wolf AL, Ellison EJ, Feig FD, Zaritsky ZJ. .
      View in: Publisher Site   Mentions:
    13. Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open. 2021 09; 7(3). Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. PMID: 34548383; PMCID: PMC8458321.
      View in: PubMed   Mentions: 10  Translation:HumansCTClinical Trials
    14. Adverse Consequences of Chronic Kidney Disease on Bone Health in Children. Semin Nephrol. 2021 09; 41(5):439-445. Kumar J, Perwad F. PMID: 34916005.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling. Sci Rep. 2021 03 17; 11(1):6175. Egli-Spichtig D, Zhang MYH, Li A, Pastor Arroyo EM, Hernando N, Wagner CA, Chang W, Perwad F. PMID: 33731726; PMCID: PMC7969776.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    16. Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia. Calcif Tissue Int. 2021 05; 108(5):622-633. Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O, Portale AA, Simmons JH, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Williams A, Nixon A, Sun W, Chen A, Skrinar A, Imel EA. PMID: 33484279; PMCID: PMC8064984.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    17. Chapter 7 The experimental detection of FGF23 responsiveness in target organs. . 2021 Jan 1; 79-97. Perwad PF, Egli-Spichtig ED. .
      View in: Publisher Site   Mentions:
    18. Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial. Bone Reports. 2020 Oct 1; 13:100654. Kamenický KP, Portale PA, Carpenter CT, Briot BK, Imel IE, Weber WT, Pitukcheewanont PP, Cheong CH, de Beur dS, Imanishi IY, Ito IN, Lachmann LR, Tanaka TH, Perwad PF, Zhang ZL, Skrinar SA, Rees RL, Insogna IK, Investigators IO. .
      View in: Publisher Site   Mentions:
    19. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease. Curr Opin Nephrol Hypertens. 2020 09; 29(5):531-536. Balani S, Perwad F. PMID: 32701599.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    20. Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study. Kidney Med. 2020 Jul-Aug; 2(4):398-406. Yokoyama JS, Matsuda-Abedini M, Denburg MR, Kumar J, Warady BA, Furth SL, Hooper SR, Portale AA, Perwad F. PMID: 32775979; PMCID: PMC7406846.
      View in: PubMed   Mentions: 6  
    21. OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial. Journal of the Endocrine Society. 2020 May 8; 4(Suppl 1). Perwad PF, Portale PA, Carpenter CT, Briot BK, Imel IE, Kamenicky KP, Weber WT, Pitukcheewanont PP, Cheong CH, De Beur DS, Imanishi IY, Ito IN, Lachmann LR, Tanaka TH, Zhang ZL, Skrinar SA, Rees RL, Insogna IK. .
      View in: Publisher Site   Mentions:
    22. α-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases. Pediatrics. 2020 05; 145(5). Cil O, Perwad F. PMID: 32245805.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    23. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. . 2019 Sep 12. EA EI, FH FG, MP MW, CF CM, LM LW, O ON, JH JS, R RP, N NN, HI HC, P PP, E ES, W WH, K KM, H HT, GS GG, A AB, F FP, M MM, CY CC, A AS, J JS, AA AP. .
      View in: Publisher Site   Mentions:
    24. Fibroblast growth factor 23 and phosphate homeostasis. Curr Opin Nephrol Hypertens. 2019 09; 28(5):465-473. Balani S, Perwad F. PMID: 31335449.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    25. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biol Blood Marrow Transplant. 2019 10; 25(10):2031-2039. Tolbert VP, Dvorak CC, Golden C, Vissa M, El-Haj N, Perwad F, Matthay KK, Vo KT. PMID: 31199983; PMCID: PMC9161973.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD. Clin J Am Soc Nephrol. 2019 07 05; 14(7):1097-1099. Perwad F, Portale AA. PMID: 31171590; PMCID: PMC6625611.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    27. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int. 2019 Sep; 105(3):271-284. Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. PMID: 31165191.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    28. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019 06 15; 393(10189):2416-2427. Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Högler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA. PMID: 31104833; PMCID: PMC7179969.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    29. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney Int. 2019 10; 96(4):890-905. Egli-Spichtig D, Imenez Silva PH, Glaudemans B, Gehring N, Bettoni C, Zhang MYH, Pastor-Arroyo EM, Schönenberger D, Rajski M, Hoogewijs D, Knauf F, Misselwitz B, Frey-Wagner I, Rogler G, Ackermann D, Ponte B, Pruijm M, Leichtle A, Fiedler GM, Bochud M, Ballotta V, Hofmann S, Perwad F, Föller M, Lang F, Wenger RH, Frew I, Wagner CA. PMID: 31301888.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    30. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. J Clin Invest. 2018 12 03; 128(12):5368-5373. Roberts MS, Burbelo PD, Egli-Spichtig D, Perwad F, Romero CJ, Ichikawa S, Farrow E, Econs MJ, Guthrie LC, Collins MT, Gafni RI. PMID: 30226830; PMCID: PMC6264742.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    31. Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury. Front Physiol. 2018; 9:1494. Egli-Spichtig D, Zhang MYH, Perwad F. PMID: 30405444; PMCID: PMC6206018.
      View in: PubMed   Mentions: 24  
    32. Vitamin D and kidney disease. Bone Rep. 2018 Dec; 9:93-100. Keung L, Perwad F. PMID: 30591927; PMCID: PMC6303542.
      View in: PubMed   Mentions: 3  
    33. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 08; 33(8):1383-1393. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators. PMID: 29947083.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCTClinical Trials
    34. Monogenic Causes of Proteinuria in Children. Front Med (Lausanne). 2018; 5:55. Cil O, Perwad F. PMID: 29594119; PMCID: PMC5858124.
      View in: PubMed   Mentions: 7  
    35. Autoimmune hyperphosphatemic tumoral calcinosis. Bone Abstracts. 2017 Jul 11. Ramnitz RM, Burbelo BP, Egli-Spichtig ED, Perwad PF, Romero RC, Ichikawa IS, Farrow FE, Econs EM, Guthrie GL, Gafni GR, Collins CM. .
      View in: Publisher Site   Mentions:
    36. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016 11 07; 11(11):1989-1998. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. PMID: 27561289; PMCID: PMC5108188.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    37. Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule. PLoS One. 2015; 10(11):e0142924. Portale AA, Zhang MY, David V, Martin A, Jiao Y, Gu W, Perwad F. PMID: 26588476; PMCID: PMC4654537.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    38. Phosphate Homeostasis and Metabolic Bone Disease. The Physiological Basis of Metabolic Bone Disease. 2014 May 27; 137-166. Perwad PF, Portale PA. .
      View in: Publisher Site   Mentions:
    39. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One. 2013; 8(9):e72816. Chanakul A, Zhang MY, Louw A, Armbrecht HJ, Miller WL, Portale AA, Perwad F. PMID: 24019880; PMCID: PMC3760837.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    40. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology. 2012 Apr; 153(4):1806-16. Zhang MY, Ranch D, Pereira RC, Armbrecht HJ, Portale AA, Perwad F. PMID: 22334725; PMCID: PMC3320256.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    41. Chapter 25 Rickets Due to Hereditary Abnormalities of Vitamin D Synthesis or Action. Pediatric Bone. 2012 Jan 1; 679-698. Portale PA, Perwad PF, Miller MW. .
      View in: Publisher Site   Mentions:
    42. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol. 2011 Dec 05; 347(1-2):17-24. Perwad F, Portale AA. PMID: 21914460.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    43. Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res. 2011 Aug; 26(8):1883-90. Ranch D, Zhang MY, Portale AA, Perwad F. PMID: 21472778; PMCID: PMC4409871.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    44. Calcium and Phosphorus. Pediatric Nephrology. 2009 Jan 1; 231-265. Portale PA, Perwad PF. .
      View in: Publisher Site   Mentions:
    45. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007 Nov; 293(5):F1577-83. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. PMID: 17699549.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    46. Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency. J Clin Endocrinol Metab. 2007 Aug; 92(8):3177-82. Kim CJ, Kaplan LE, Perwad F, Huang N, Sharma A, Choi Y, Miller WL, Portale AA. PMID: 17488797.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    47. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005 Dec; 146(12):5358-64. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. PMID: 16123154.
      View in: PubMed   Mentions: 166     Fields:    Translation:Animals
    Farzana's Networks
    Concepts (144)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.